Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.00 USD | +1.48% |
|
+4.54% | +5.11% |
Feb. 11 | Exelixis, Inc., Q4 2024 Earnings Call, Feb 11, 2025 | |
Feb. 11 | Exelixis' Q4 Non-GAAP Earnings, Revenue Rise | MT |
Business description: Exelixis, Inc.
Number of employees: 1,147
Sales by Activity: Exelixis, Inc.
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Discovery, Development & Commercialization of New Medicines for Difficult-To-Treat Cancers | 988M | 1.43B | 1.61B | 1.83B | 2.17B |
Geographical breakdown of sales: Exelixis, Inc.
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
United States (U.S.) | 753M | 1.09B | 1.41B | 1.65B | 1.82B |
Europe | 152M | 302M | 169M | 145M | 319M |
Japan | 83.02M | 43.5M | 28.73M | 39.49M | 27.08M |
Managers: Exelixis, Inc.
Director | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 64 | 2010-07-21 | |
Director of Finance/CFO | 57 | 2015-07-14 | |
Amy Peterson
CTO | Chief Tech/Sci/R&D Officer | 58 | 2023-08-22 |
Dana Aftab
COO | Chief Operating Officer | - | 2016-01-31 |
Susan T. Hubbard
IRC | Investor Relations Contact | - | 2016-11-30 |
Members of the board: Exelixis, Inc.
Manager | Title | Age | Since |
---|---|---|---|
Director/Board Member | 69 | 2004-01-31 | |
George Poste
BRD | Director/Board Member | 80 | 2004-07-31 |
Chairman | 76 | 1997-12-31 | |
Director/Board Member | 64 | 2010-07-21 | |
Julie Smith
BRD | Director/Board Member | 54 | 2016-09-21 |
Maria Freire
BRD | Director/Board Member | 70 | 2018-04-04 |
Tomas Jan Heyman
BRD | Director/Board Member | 69 | 2023-05-30 |
David Johnson
BRD | Director/Board Member | 42 | 2023-05-30 |
Robert Oliver
BRD | Director/Board Member | 66 | 2023-05-30 |
Mary Beckerle
BRD | Director/Board Member | 70 | 2024-01-04 |
Company details: Exelixis, Inc.

Bio Therapeutic Drugs
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+1.48% | +4.54% | +71.65% | +88.27% | 9.8B | ||
-0.77% | -2.20% | +9.84% | +98.50% | 118B | ||
-0.10% | -5.13% | -28.93% | +8.03% | 72.09B | ||
-2.13% | -3.83% | +68.23% | +140.90% | 38.79B | ||
-2.40% | +1.89% | +31.02% | -22.46% | 28.73B | ||
+2.38% | +3.29% | +58.26% | +12.45% | 24.63B | ||
+4.61% | +2.25% | +11.97% | -30.27% | 23.61B | ||
-2.06% | +6.27% | +380.22% | +952.71% | 15.76B | ||
+0.81% | -0.80% | +189.03% | +244.83% | 14.19B | ||
+0.94% | +8.59% | -19.89% | -31.61% | 13.46B | ||
Average | +0.28% | +1.41% | +77.14% | +146.14% | 35.89B | |
Weighted average by Cap. | -0.21% | -1.00% | +37.44% | +98.99% |
Sector

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EXEL Stock
- Company Exelixis, Inc.